U-Blot® IGHE hIgG1 Reference Antibody(Omalbio)

Background:Omalizumab achieves its efficacy by targeting and neutralizing IgE (immunoglobulin E) . Ige plays an important role in allergic reactions, and Omalizumab reduces its amount, thereby reducing the occurrence of allergic symptoms. IgE-related research has driven the development of IgE-targeted biologics, and omalizumab, as the first anti-IgE agent, has demonstrated clear efficacy in moderate-to-severe asthma and chronic spontaneous urticaria, and has been used in the treatment of asthma and chronic urticaria, it provides a new option for patients who do not respond well to traditional treatments.